[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
IJRR Information::
About the Journal
Editorial Board
Keywords
For Authors::
Aims and Scope
Call for Papers
Submission Instructions
For Reviewers::
Referee page
Subscription::
Subscription Form
News & Events::
Journal News
Web Mail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
ISSN
Hard Copy 2322-3243
Online 2345-4229
..
Online Submission
Now you can send your articles to IJRR office using the article submission system.
..

AWT IMAGE

AWT IMAGE
Volume 22, Issue 2 (4-2024)                   Int J Radiat Res 2024, 22(2): 283-287 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Zhou R, Cai Z, Yuan Y, Zhou Z, Ding H, Cheng Y, et al . Study on the application value of combined detection of multiple tumor markers in lung cancer classification diagnosis. Int J Radiat Res 2024; 22 (2) :283-287
URL: http://ijrr.com/article-1-5393-en.html
Study on the application value of combined detection of multiple tumor markers in lung cancer classification diagnosis
RM. Zhou , ZH. Cai , YR. Yuan , ZL. Zhou , H. Ding , YQ. Cheng , L. Liang , ZN. Tuo
Department of Respiratory and Critical Care Medicine, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, China , gyliangli@outlook.com
Abstract:   (1433 Views)
Background: To evaluate the value of six tumor markers including squamous cell carcinoma antigen (SCCA), cytokeratin 19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), glycoconjugate antigen 125 (CA125), neuron-specific enolase (NSE), along with gastrin-releasing peptide precursor (ProGRP) in the diagnosis and pathological staging of lung cancer (LC) alone or in combination. Materials and Methods: A retrospective analysis was performed on 300 patients of which 62 cases were diagnosed as small cell lung cancer (SCLC), 105 adenocarcinoma (LUAD), 41 squamous cell carcinoma (LUSC) and 92 large cell lung cancer (LCLC) by histopathology. Another 364 patients with benign lung disease in the same period were chosen for the benign lung disease group. Results: The detection results of 6 tumor markers in serum of LC, SCCA, NSE and ProGP patients with different pathological types were higher compared with lung benign lesions group (P<0.01). LC can be separated into SCLC along with non-Small cell lung cancer (NSCLC) by NSE+ProGRP combination. The detection rate of lung squamous cell carcinoma by SCCA+ cytokeratin 19 fragment (CYFRA21-1) was higher than that by CEA+CA125 combination for adenocarcinoma. The combined determination of NSE and ProGRP was highly sensitive to SCLC. In NSCLC, the combined detection of SCC-Ag and CYFRA21-1 showed high sensitivity to LUSC. CEA+CA125 combined detection was highly sensitive to LUAD. Conclusion: The combined determination of NSE and ProGRP was highly sensitive to SCLC. CEA+CA125 combined detection was highly sensitive to LUAD, and SCCA+CYFR21-1+CEA+CA125 was the best combined detection analysis of multiple indexes.
Keywords: Squamous cell carcinoma antigen, CYFRA21-1, carcinoembryonic antigen, lung cancer.
Full-Text [PDF 584 kb]   (388 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
References
1. 1. Lu S, Kong H, Hou Y, et al., (2018) Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer. Lung Cancer, 123: p. 44-51. [DOI:10.1016/j.lungcan.2018.06.027]
2. García-Giménez JL, Seco-Cervera M, Tollefsbol TO, et al. (2017) Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory. Crit Rev Clin Lab Sci, 54(7-8): 529-550. [DOI:10.1080/10408363.2017.1410520]
3. Bray F, Ferlay J, Soerjomataram I, et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68(6): 394-424. [DOI:10.3322/caac.21492]
4. Ferlay J, Colombet M, Soerjomataram I, et al. (2018) Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer, 103: 356-387. [DOI:10.1016/j.ejca.2018.07.005]
5. Chen W, Zheng R, Baade PD, et al. (2016) Cancer statistics in China, 2015. CA Cancer J Clin, 66(2): 115-32. [DOI:10.3322/caac.21338]
6. Bi H, Yin L, Fang W, et al. (2022) Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer. Lab Med, 2022. [DOI:10.1093/labmed/lmac122]
7. Wang H, Zhang X, Liu X, et al. (2016) Diagnostic value of bronchoalveolar lavage fluid and serum tumor markers for lung cancer. J Cancer Res Ther, 12(1): 355-8. [DOI:10.4103/0973-1482.162111]
8. Wang CF, Peng SJ, Liu RQ, et al. (2020) The Combination of CA125 and NSE Is Useful for Predicting Liver Metastasis of Lung Cancer. Dis Markers, 2020: 8850873. [DOI:10.1155/2020/8850873]
9. Xu CM, Luo YL, Li S, et al. (2019) Multifunctional neuron-specific enolase: its role in lung diseases. Biosci Rep, 39(11). [DOI:10.1042/BSR20192732]
10. Hu Q, Xiao P, Li J, Yu P (2016) A retrospective analysis of serum tumor markers found in non-small cell lung cancer. J Cancer Res Ther, 12(1): 117-20. [DOI:10.4103/0973-1482.151424]
11. Homma S, Harada M, Yano H, et al. (2006) Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients. Int J Oncol, 29(3): 577-87. [DOI:10.3892/ijo.29.3.577]
12. Shan Y, Yin X, Zhao N, et al. (2021) Comparison of serum tumor markers combined with dual-source CT in the diagnosis of lung cancer. Minerva Med, 2021.
13. Hong Y, Xin Y, Yue F, et al. (2017) Randomized clinical trial comparing the effects of sevoflurane and propofol on carbon dioxide embolism during pneumoperitoneum in laparoscopic hepatectomy. Oncotarget, 8(16): 27502-27509. [DOI:10.18632/oncotarget.15492]
14. Cho A, Hur J, Moon YW, et al. (2016) Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. BMC Cancer, 16: 224. [DOI:10.1186/s12885-016-2251-z]
15. Salgia R, Harpole D, Herndon JE, et al. (2001) 2nd, E. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res, 21(2b): 1241-6.
16. Wang J, Gao J, He J (2010) Diagnostic value of ProGRP and NSE for small cell lung cancer: a meta-analysis. Zhongguo Fei Ai Za Zhi, 13(12): 1094-100.
17. Shibayama T, Ueoka H, Nishii K, et al. (2001) Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer, 32(1): 61-9. [DOI:10.1016/S0169-5002(00)00205-1]
18. Barchiesi V, Simeon V, Sandomenico C, et al. (2021) Circulating progastrin-releasing peptide in the diagnosis of Small Cell Lung Cancer (SCLC) and in therapeutic monitoring. J Circ Biomark, 10: 9-13. [DOI:10.33393/jcb.2021.2212]
19. Wójcik E, Kulpa JK, Sas-Korczyńska B, et al. (2008) ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res, 28(5b): 3027-33.
20. Kato Y, Tanaka Y, Hino M, Gemma A (2019) ProGRP as early predictive marker of non-small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment. Respir Med Case Rep, 27: 100837. [DOI:10.1016/j.rmcr.2019.100837]
21. Dong A, Zhang J, Chen X, et al. (2019) Diagnostic value of ProGRP for small cell lung cancer in different stages. J Thorac Dis, 11(4): 1182-1189. [DOI:10.21037/jtd.2019.04.29]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
International Journal of Radiation Research
Persian site map - English site map - Created in 0.06 seconds with 48 queries by YEKTAWEB 4718